Updated Jul 16, 2026
Finley John David has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $310K.
John David Finley is an executive involved with Palisade Bio, Inc., where he has served as Director, CEO, and CFO. The company focuses on developing therapeutics for intestinal barrier integrity.
| Role | CEO, CFO, Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-08 | PALI | PALISADE BIO, INC. | M — Option exercise | 133 | $0.70 | $93 |
| 2026-07-08 | PALI | PALISADE BIO, INC. | S — Open-market sale | 146.8K | $2.07 | $303K |
| 2026-07-08 | PALI | PALISADE BIO, INC. | M — Option exercise | 335.2K | — | |
| 2026-02-14 | PALI | PALISADE BIO, INC. | S — Open-market sale | 3.9K | $1.75 | $7K |
| 2026-02-14 | PALI | PALISADE BIO, INC. | M — Option exercise | 13.3K | — |
John David Finley is an executive involved with Palisade Bio, Inc., where he has served as Director, CEO, and CFO. The company focuses on developing therapeutics for intestinal barrier integrity.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($310K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Finley John David profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.